DelveInsight has launched a new Report on “Duchenne Muscular Dystrophy Market Insights, Epidemiology and Market Forecast-2030” to its portfolio.
DelveInsight’s “Duchenne Muscular Dystrophy – Market Insights, Epidemiology, and Market Forecast-2030“ report delivers an in-depth understanding of the Duchenne Muscular Dystrophy, historical and forecasted epidemiology as well as the Duchenne Muscular Dystrophy market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
Key Highlights from the report are:
Request for free sample report: https://www.delveinsight.com/sample-request/duchenne-muscular-dystrophy-market
Duchenne Muscular Dystrophy is a progressive form of muscular dystrophy, which usually occurs in males, though in rare cases may affect females as well, causing progressive weakness and loss (atrophy) of skeletal and heart muscles.
The disease epidemiology covered in the report proffers historical as well as forecasted Duchenne Muscular Dystrophy epidemiology, which is segmented as Diagnosed Prevalent Population of DMD, Age-specific Diagnosed Prevalence of DMD, Mutation-specific Diagnosed Prevalence of DMD and Diagnosed Prevalence of Associated Comorbidities in DMD in the 7MM market from 2017 to 2030.
The report also covers Mutation-specific Diagnosed Prevalence of Duchenne Muscular Dystrophy, including several mutations such as Large Mutations, Small Mutations and Point Mutations with major proportion for deletions in Large Mutations subgroup.
Duchenne Muscular Dystrophy report encloses the detailed analysis of DMD marketed drugs and mid and late-stage pipeline drugs.
The therapies that are approved for the DMD treatment are Vyondys 53 (Golodirsen), Emflaza, Exondys 51, Translarna along with many more.
Drugs covered in the report are:-
There are several key players robustly involved in developing potential products such as
And many others
Key Players covered in the DMD market report are:-
The reasons for buying this report:
Table of Contents
1
Key Insights
2
Duchenne Muscular Dystrophy Market Overview at a Glance
3
DMD Disease Background and Overview
4
Recognized Establishments
5
Duchenne Muscular Dystrophy Epidemiology and Patient Population
6
Country Wise-Epidemiology of DMD
6.1
United States
6.2
EU5 Countries
6.3
Germany
6.4
France
6.5
Italy
6.6
Spain
6.7
United Kingdom
6.8
Japan
7
Duchenne Muscular Dystrophy Treatment
8
General Guidelines on DMD
9
United States Guidelines on Duchenne Muscular Dystrophy
10
European Guidelines on Duchenne Muscular Dystrophy
11
Unmet Needs
12
DMD Marketed Drugs
13
Duchenne Muscular Dystrophy Emerging Drugs
13.1
Key Cross Competition
13.2
Casimersen: Sarepta Therapeutics
13.3
Puldysa (Idebenone): Santhera Pharmaceuticals
13.4
Givinostat: Italfarmaco
13.5
Edasalonexent: Catabasis Pharmaceuticals
13.6
Viltolarsen: Nippon Shinyaku (NS Pharma)
13.7
PF-06939926: Pfizer
13.8
Vamorolone: Santhera Pharmaceuticals/ReveraGen BioPharma
13.9
TAS-205: Taiho Pharmaceutical
13.10
Pamrevlumab (FG-3019): FibroGen
13.11
SRP-9001: Sarepta Therapeutics
13.12
Allogeneic Cardiosphere-Derived Cells (CAP-1002): Capricor
13.13
DS-5141b: Daiichi Sankyo
14
Duchenne Muscular Dystrophy 7 Major Market Analysis
15
The United States Market Outlook
16
EU-5 Countries: Market Outlook
16.1
16.2
16.3
16.4
16.5
17
Japan: Market Outlook
18
Case Reports
19
Market Drivers
20
Market Barriers
21
SWOT Analysis for Duchenne Muscular Dystrophy
22
Appendix
23
DelveInsight Capabilities
24
Disclaimer
25
About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end to end comprehensive solutions to improve their performance.
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Ankit NigamEmail: Send EmailPhone: 9193216187Address:304 S. Jones Blvd #2432 City: AlbanyState: New YorkCountry: United StatesWebsite: https://www.delveinsight.com/report-store/duchenne-muscular-dystrophy-market